KetamineOne Applies Cutting-Edge Tech & Research to Enhance Psychedelic Therapies Across Growing Clinic Network
August 11th, 2021
App, Exclusive, Psychedelics, Top Story
The psychedelic renaissance has taken the research community by storm, but psilocybin, DMT, MDMA, and other therapies remain in development. Ketamine is the only widely available psychedelic therapy that the FDA approves to treat depression and suicidal ideations. As a result, investors may want to start there for near-term opportunities.
Let’s take a look at ketamine’s expanding therapeutic potential and new approaches to enhancing mental health treatments.
Ketamine’s Growing Promise
Ketamine is a popular medication for starting and maintaining anesthesia—a trance-like state providing pain relief, sedation and amnesia. Since it increases blood pressure and preserves breathing airways, the drug is commonplace in emergencies and warzones where patients are at risk for hypotension while breathing equipment may be unavailable.
More recently, researchers have been studying ketamine for its antidepressant properties. For example, intravenous ketamine infusions in patients with treatment-resistant depression result in mood improvements within four hours, reaching a peak in 24 hours. In addition, a significant minority of patients go on to experience relief for 30 days or more.
In March 2019, the FDA approved an esketamine nasal spray, in conjunction with an oral antidepressant, to treat depression in adults who have tried other antidepressant medicines but have not benefited from them. According to FutureWise Research, the global treatment-resistant depression market could surpass $1 billion by the end of 2026.
In August 2020, the FDA expanded the approval to cover patients experiencing suicidal ideations. While existing drugs take weeks to work, esketamine can reduce symptoms within 24 hours after the first dose, making it far more productive. And Coherent Market Insights believes that the suicide prevention market could reach $5.5 billion by 2027.
Data Bridge Market Research projects that the psychedelics market as a whole will grow at a 16.3% compound annual growth rate between 2020 and 2027, reaching nearly $7 billion in annual sales by the end of the forecast period. Companies using ketamine as a stepping stone in the industry could be best positioned to capitalize over the long term.
KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) is building a network of North American medical clinics focusing on ketamine-enhanced treatments. Thus far, the company has acquired 16 clinics across North America (15 in Canada and one in the United States) with letters of intent to acquire an additional three clinics, making it one of the most mature companies in the space.
The company is enhancing these ketamine-based therapies through the use of next-generation technologies. For instance, the company recently signed an exclusive agreement to license OVR Tech LLC’s INHALE Wellness Platform, which combines scent-enabled technology with immersive virtual reality to deepen a patient’s psychedelic treatment experience.
Another example is the company’s partnership with the Health Canada-approved NeuroCatch Platform. As part of that deal, the company is leveraging the breakthrough technology in its Integrated Rehab and Performance clinic in Victoria, BC, to measure brain function in injured veterans and customize therapies to assist them.
The company’s recent acquisition of KGK Science Inc. also adds a contract research division capable of performing cutting-edge clinical research. In fact, the company is already working with five unique clients to conduct psychedelic-driven studies, including two ongoing clinical trials leveraging its network of vertically-integrated clinics.
Combining virtual reality, wearables, and digital therapeutics could help differentiate the company’s medical clinics, while the facilities themselves provide a valuable patient base to advance psychedelic research. The move also enables the company to quickly pivot into other psychedelic substances as they become legal.
Ketamine is quickly becoming mainstream for treatment-resistant depression and suicidal ideations. In addition to becoming a premier operator of ketamine clinics across North America, KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) is leveraging new technologies to enhance psychedelic experiences and therapeutic outcomes.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.